{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:23:26Z","timestamp":1773901406307,"version":"3.50.1"},"reference-count":36,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Viral Immunology"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>The respiratory syncytial virus (RSV) is a major cause of acute lower respiratory tract infection in children and poses a significant risk to older adults. Developing a vaccine against RSV has been a priority, and the recently approved Arexvy vaccine has shown promise in preventing lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older. This comprehensive review discusses the history of RSV, challenges in vaccine development, and the mechanism of action of Arexvy. The efficacy and safety of the vaccine are explored based on phase 3 clinical trial, demonstrating its effectiveness in preventing RSV-associated LRTD. The most common adverse reactions reported include injection site pain, fatigue, myalgia, headache, and arthralgia. Ongoing research focuses on the long-term effectiveness of Arexvy, including the need for booster doses and its impact on reducing RSV-associated hospitalizations. The potential of Arexvy to lessen the burden of RSV-related illnesses, particularly in vulnerable populations, is highlighted, emphasizing the importance of widespread immunization efforts and accessibility to this groundbreaking vaccine.<\/jats:p>","DOI":"10.1089\/vim.2023.0093","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T13:45:21Z","timestamp":1707140721000},"page":"12-15","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Arexvy: A Comprehensive Review of the Respiratory Syncytial Virus Vaccine for Revolutionary Protection"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9542-461X","authenticated-orcid":false,"given":"M","family":"Swathi","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Bapuji Pharmacy College, Rajiv Gandhi University of Health Sciences, Davangere, Karnataka, India."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,2,13]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/2049936119865798"},{"issue":"3","key":"e_1_3_4_3_1","first-page":"281","article-title":"Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization","volume":"66","author":"Chanock RO","year":"1957","unstructured":"Chanock RO, , Roizman BE. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am J Hyg, 1957; 66(3):281\u2013290.","journal-title":"Am J Hyg"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00211-07"},{"issue":"8","key":"e_1_3_4_5_1","first-page":"785","article-title":"RSV prevention in infants","volume":"376","author":"Chu HY","year":"2017","unstructured":"Chu HY, , Englund JA, , Griffin MR. RSV prevention in infants. N Engl J Med, 2017; 376(8):785\u2013786.","journal-title":"N Engl J Med"},{"key":"e_1_3_4_6_1","unstructured":"Clinical Trials Arena. Arexvy (RSV vaccine) to Prevent Lower Respiratory Tract Disease (LRTD) USA. Progressive Digital Media Group: London UK; Updated on May 17 2023. Available from: https:\/\/www.clinicaltrialsarena.com\/projects\/arexvy-prevent-lower-respiratory-tract-disease\/ [Last accessed: July10 2023]."},{"key":"e_1_3_4_7_1","unstructured":"ClinicalTrials.gov. Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above. National Library of Medicine: Bethesda MD USA; Updated on June 30 2023. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04886596 [Last accessed: July10 2023]."},{"key":"e_1_3_4_8_1","unstructured":"DailyMed. AREXVY-Respiratory Syncytial Virus Vaccine Recombinant Adjuvanted Kit. National Library of Medicine: Bethesda MD USA; Updated on May 3 2023. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=1e50f275-002e-413f-a840-66ee3cb3740c [Last accessed: July10 2023]."},{"key":"e_1_3_4_9_1","unstructured":"European Medicines Agency. AREXVY-Respiratory Syncytial Virus (RSV) vaccine (recombinant adjuvanted). Amsterdam the Netherlands. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/arexvy-epar-product-information_en.pdf [Last accessed: July11 2023]."},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043951"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aar3534"},{"key":"e_1_3_4_12_1","unstructured":"Foley T Moore S Quinn K et al. US FDA approves GSK's RSV vaccine for older adults."},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004883.pub2"},{"key":"e_1_3_4_14_1","unstructured":"GlaxoSmithKline. Arexvy [package insert]. Research Triangle Park NC: GlaxoSmithKline; 2023. Section 14.1 Efficacy in Adults 60 Years of Age and Older. Available from: https:\/\/www.fda.gov\/media\/167805\/download [Last accessed: July7 2023]."},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1986.02140200053026"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913556"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00010-16"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-4453(84)94075-1"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21377"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02193-17"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1243283"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.03.017"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-92-22538"},{"issue":"10","key":"e_1_3_4_24_1","first-page":"e259","article-title":"The state of respiratory syncytial virus (RSV) vaccine research: A systematic review","volume":"17","author":"Munoz FM","year":"2017","unstructured":"Munoz FM, , Piedra PA, , Glezen WP, et al. The state of respiratory syncytial virus (RSV) vaccine research: A systematic review. Lancet Infect Dis, 2017; 17(10):e259\u2013e267.","journal-title":"Lancet Infect Dis"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60206-1"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5021"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1526-0542(04)90023-1"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209604"},{"issue":"18","key":"e_1_3_4_29_1","first-page":"1837","article-title":"Vaccine policy changes and epidemiology of infections due to Streptococcus pneumoniae serotype 19A in children in the United States","volume":"316","author":"Polack FP","year":"2016","unstructured":"Polack FP, , Atkinson WL, , Sahni LC, et al. Vaccine policy changes and epidemiology of infections due to Streptococcus pneumoniae serotype 19A in children in the United States. JAMA, 2016; 316(18):1837\u20131848.","journal-title":"JAMA"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2022.10.001"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.64762"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-4453(84)90530-9"},{"issue":"11","key":"e_1_3_4_33_1","first-page":"2297","article-title":"Challenges in the development of a respiratory syncytial virus vaccine","volume":"15","author":"Tremblay KD","year":"2019","unstructured":"Tremblay KD, , Krempl C, , Manitopyes N. Challenges in the development of a respiratory syncytial virus vaccine. Hum Vaccin Immunother, 2019; 15(11):2297\u20132304.","journal-title":"Hum Vaccin Immunother"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00991-7"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S60710"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(23)00195-7"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21377"}],"container-title":["Viral Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/vim.2023.0093","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/vim.2023.0093","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/vim.2023.0093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:35:23Z","timestamp":1773246923000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/vim.2023.0093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1089\/vim.2023.0093"],"URL":"https:\/\/doi.org\/10.1089\/vim.2023.0093","relation":{},"ISSN":["0882-8245","1557-8976"],"issn-type":[{"value":"0882-8245","type":"print"},{"value":"1557-8976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}